A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy : results from FIRE-3 and JACCRO 05 and 06 trials
Sebio, A. (Institut d'Investigació Biomèdica Sant Pau)
Stintzing, Sebastian (Department of Hematology and Oncology, Klinikum der Universitat, University of Munich)
Heinemann, V. (Department of Hematology and Oncology, Klinikum der Universitat, University of Munich)
Sunakawa, Yu (Keck School of Medicine, University of Southern California)
Zhang, W. (Keck School of Medicine, University of Southern California)
Ichikawa, W. (Division of Medical Oncology, Showa University)
Tsuji, A. (Department of Clinical Oncology, Kagawa University)
Takahashi, T. (Division of Medical Oncology, Showa University)
Parek, A. (Keck School of Medicine, University of Southern California)
Yang, D. (Keck School of Medicine, University of Southern California)
Cao, S. (Keck School of Medicine, University of Southern California)
Ning, Y. (Keck School of Medicine, University of Southern California)
Stremitzer, Stefan (Keck School of Medicine, University of Southern California)
Matsusaka, S. (Keck School of Medicine, University of Southern California)
Okazaki, S. (Keck School of Medicine, University of Southern California)
Barzi, A. (Keck School of Medicine, University of Southern California)
Berger, M. (Keck School of Medicine, University of Southern California)
Lenz, H-J (Keck School of Medicine, University of Southern California)
Universitat Autònoma de Barcelona

Data:	2016
Resum:	The Hippo pathway is involved in colorectal cancer (CRC) development and progression. The Hippo regulator Rassf1a is also involved in the Ras signaling cascade. In this work, we tested single nucleotide polymorphisms within Hippo components and their association with outcome in CRC patients treated with cetuximab. Two cohorts treated with cetuximab plus chemotherapy were evaluated (198 RAS wild-type (wt) patients treated with first-line FOLFIRI plus Cetuximab within the FIRE-3 trial and 67 Ras wt patients treated either with first-line mFOLFOX6 or SOX plus Cetuximab). In these two populations, Rassf1a rs2236947 was associated with overall survival, as patients with a CC genotype had significantly longer OS compared to those with CA or AA genotypes. This association was stronger in patients with left-side CRC [HR: 1. 79 (1. 01-3. 14); P =0. 044 and HR: 2. 83 (1. 14-7. 03); P =0. 025, for Fire 3 and JACCRO cohorts, respectively]. Rassf1a rs2236947 is a promising biomarker for patients treated with cetuximab plus chemotherapy.
Ajuts:	Instituto de Salud Carlos III JR14-00006
Drets:	Tots els drets reservats.
Llengua:	Anglès
Document:	Article ; recerca ; Versió acceptada per publicar
Matèria:	Rassf1a ; Cetuximab ; SNP ; Colorectal cancer ; Biomarker
Publicat a:	The pharmacogenomics journal, october 2016, ISSN 1473-1150

DOI: 10.1038/tpj.2016.69
PMID: 27698403

15 p, 594.2 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats